Patients who undergo valve-in-valve transcatheter aortic valve replacement (ViV-TAVR), have fewer periprocedural complications and similar rates of all-cause mortality at 2 years as compared with redo surgical aortic valve replacement (SAVR), a new retrospective study shows.